Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Total Current Liabilities (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 5 years of Total Current Liabilities data on record, last reported at $2.7 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities fell 21.36% year-over-year to $2.7 million; the TTM value through Sep 2025 reached $2.7 million, down 21.36%, while the annual FY2024 figure was $4.5 million, 51.01% up from the prior year.
  • Total Current Liabilities reached $2.7 million in Q3 2025 per COEP's latest filing, down from $4.5 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $5.7 million in Q1 2025 and bottomed at $31816.0 in Q1 2021.
  • Average Total Current Liabilities over 5 years is $2.5 million, with a median of $2.7 million recorded in 2025.
  • The widest YoY moves for Total Current Liabilities: up 3976.05% in 2022, down 21.42% in 2022.
  • A 5-year view of Total Current Liabilities shows it stood at $2.8 million in 2021, then decreased by 21.42% to $2.2 million in 2022, then skyrocketed by 37.56% to $3.0 million in 2023, then soared by 51.01% to $4.5 million in 2024, then crashed by 40.06% to $2.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $2.7 million in Q3 2025, $4.5 million in Q2 2025, and $5.7 million in Q1 2025.